隶属于 doosan corp.
相关临床试验
51
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1918
进行中（未招募）
3
5.9%
已完成
22
43.1%
尚未招募
5
9.8%
招募中
17
33.3%
Unknown
4
7.8%
暂无批准数据
- Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizyme™), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers. - The randomized, double-blind, placebo-controlled study evaluates both allergenicity through intradermal administration and safety via subcutaneous delivery of the investigational biologic. - The company plans to submit a Biological License Application to South Korea's MFDS by the second half of 2025, representing a significant milestone for its HyDIFFUZE™ platform technology. - HLB3-002 is designed to enable subcutaneous delivery of therapeutics as an alternative to traditional intravenous administration, potentially improving patient convenience and reducing healthcare costs.
- A multicenter, randomized encouragement design trial is underway to assess the impact of Widely Integrated Services in Home (WISH) on homebound older adults. - The WISH intervention includes interprofessional care teams providing healthcare and family counseling services through regular home visits. - The primary outcomes measured are community survival days, avoidable hospitalizations, and the rate of dying at home for participants. - The study uses a post-randomization consent design and CACE analytic methods to address potential biases and ensure real-world applicability.
